Association of Blood Pressure Genetic Risk Score with Cardiovascular Disease and CKD Progression: Findings from the CRIC Study
Authors:
- Jovia L. NierenbergJNJovia L. Nierenberg
- Jiang HeJHJiang He
- Anand SrivastavaASAnand Srivastava
- Jordana B. CohenJCJordana B. Cohen
- Santosh L. SarafSSSantosh L. Saraf
- Tanika N. KellyTKTanika N. Kelly
- CRIC Study InvestigatorsCICRIC Study Investigators
- 26 August 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 2 (8) , 1251-1260
Abstract
Background: In the general population, genetic risk for high BP has been associated with cardiovascular disease, but not kidney function or incident CKD. These relationships have not been studied longitudinally in participants with CKD. We examined whether BP genetic risk predicts cardiovascular disease and kidney disease progression in patients with CKD. Methods: We included 1493 African- and 1581 European-ancestry participants from the Chronic Renal Insufficiency Cohort who were followed for 12 years. We examined associations of BP genetic risk scores with development of cardiovascular disease (myocardial infarction, congestive heart failure, or stroke) and CKD progression (incident ESKD or halving of eGFR) using Cox proportional hazards models. Analyses were stratified by race and included adjustment for age, sex, study site, and ancestry principal components. Results: Among European-ancestry participants, each SD increase in systolic BP and pulse pressure genetic risk score conferred a 15% (95% CI, 4% to 27%) and 11% (95% CI, 1% to 23%), respectively, higher risk of cardiovascular disease, with a similar, marginally significant trend for diastolic BP. Among African-ancestry participants, each SD increase in systolic and diastolic BP genetic risk score conferred a 10% (95% CI, 1% to 20%) and 9% (95% CI, 0% to 18%), respectively, higher risk of cardiovascular disease. Higher genetic risk was not associated with CKD progression. Conclusions: Genetic risk for elevation in BP was associated with increased risk of cardiovascular disease, but not CKD progression.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, U24DK060990, K23DK120811, U2CDK114886, P30DK114857, NM R01DK119199)
- National Center for Advancing Translational Sciences (UL1TR000003, UL1TR000424, UL1TR000433, UL1TR000439)
- National Institutes of Health (M01 RR-16500)
- Center for Clinical and Translational Science, University of Illinois at Chicago (UL1RR029879)
- National Institute of General Medical Sciences (P20 GM109036)
This publication has 38 references indexed in Scilit:
- High Trans-ethnic Replicability of GWAS Results Implies Common Causal VariantsPLOS Genetics, 2013
- Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressureNature Genetics, 2011
- Genetic variants in novel pathways influence blood pressure and cardiovascular disease riskNature, 2011
- Risk of Incident ESRD: A Comprehensive Look at Cardiovascular Risk Factors and 17 Years of Follow-up in the Atherosclerosis Risk in Communities (ARIC) StudyAmerican Journal of Kidney Diseases, 2010
- Chronic Renal Insufficiency Cohort (CRIC) StudyClinical Journal of the American Society of Nephrology, 2009
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressureStatistics in Medicine, 2005
- The Chronic Renal Insufficiency Cohort (CRIC) StudyJournal of the American Society of Nephrology, 2003
- Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonistsKidney International, 2000
- Blood Pressure and End-Stage Renal Disease in MenNew England Journal of Medicine, 1996